We are live on
!
Find out more
Parallel Advisors Portfolio holdings
AUM
$6.56B
Turnover
11.49%
1-Year Est. Return
32.24%
This Fund
S&P 500
This Quarter
Est. Return
+8.88%
1 Year Est. Return
+32.24%
3 Year Est. Return
+108.68%
5 Year Est. Return
+114.41%
10 Year Est. Return
–
AUM
$5B
AUM Growth
+$569M
(+13%)
Cap. Flow
+$104M
Cap. Flow
% of AUM
2.08%
Top 10 Holdings %
Top 10 Hldgs %
38.84%
Holding
3,762
New
251
Increased
1,450
Reduced
1,277
Closed
224
Avg Time Held Equity + Options
4.7
years
Top 10 Avg Time Held Equity + Options
2.9
years
Top 20 Avg Time Held Equity + Options
3.8
years
Avg Time Held Equity only
4.7
years
Top 10 Avg Time Held Equity only
2.9
years
Top 20 Avg Time Held Equity only
3.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$18.4M |
| 2 |
iShares Core S&P Total US Stock Market ETF
ITOT
|
+$9.77M |
| 3 |
BlackRock US Equity Factor Rotation ETF
DYNF
|
+$5.48M |
| 4 |
Microsoft
MSFT
|
+$4.93M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$4.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Corcept Therapeutics
CORT
|
+$7.34M |
| 2 |
Starbucks
SBUX
|
+$4.7M |
| 3 |
iShares California Muni Bond ETF
CMF
|
+$3.3M |
| 4 |
Invesco S&P 500 Equal Weight ETF
RSP
|
+$2.63M |
| 5 |
Vanguard Morningstar Small-Cap ETF
VB
|
+$1.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 46.71% |
| 2 | Technology | 17.21% |
| 3 | Healthcare | 9.68% |
| 4 | Financials | 7.2% |
| 5 | Communication Services | 5.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3051
Asbury Automotive
ABG
$3.05B
| $1.67K | ﹤0.01% |
7
-14
| -67% | -$3.2K |
2024 Q2
4 quarters
|
|
3052
Liquidia Corp
LQDA
$3.11B
| $1.67K | ﹤0.01% |
134
| – | – |
2024 Q3
3 quarters
|
|
3053
Papa John's
PZZA
$644M
| $1.66K | ﹤0.01% |
34
-304
| -90% | -$12.4K |
2019 Q1
25 quarters
|
|
3054
Teladoc Health
TDOC
$1.08B
| $1.66K | ﹤0.01% |
191
-1,621
| -89% | -$11.7K |
2018 Q3
27 quarters
|
|
3055
Willamette Valley Vineyards
WVVI
$10.5M
| $1.66K | ﹤0.01% |
300
| – | – |
2016 Q4
34 quarters
|
|
3056
Nathan's Famous
NATH
$417M
| $1.66K | ﹤0.01% |
15
+4
| +36% | +$408 |
2024 Q4
2 quarters
|
|
3057
Beam Therapeutics
BEAM
$2.55B
| $1.65K | ﹤0.01% |
97
-18
| -16% | -$313 |
2020 Q4
18 quarters
|
|
3058
Definium Therapeutics
DFTX
$4.6B
| $1.63K | ﹤0.01% |
252
+233
| +1,226% | +$1.53K |
2022 Q2
12 quarters
|
|
3059
AMN Healthcare
AMN
$1.55B
| $1.63K | ﹤0.01% |
79
-30
| -28% | -$624 |
2025 Q1
1 quarter
|
|
3060
DELISTED
Dynavax Technologies
DVAX
| $1.63K | ﹤0.01% |
164
-1,892
| -92% | -$19.9K |
2024 Q2
4 quarters
|
|
3061
NCR Atleos
NATL
$3.4B
| $1.63K | ﹤0.01% |
57
-8
| -12% | -$216 |
2023 Q4
6 quarters
|
|
3062
Eagle Bancorp
EGBN
$854M
| $1.62K | ﹤0.01% |
83
-19
| -19% | -$353 |
2023 Q2
8 quarters
|
|
3063
NYLIM Hedge Multi-Strategy Tracker ETF
QAI
$1,000M
| $1.62K | ﹤0.01% |
50
-1,478
| -97% | -$46.5K |
2023 Q2
8 quarters
|
|
3064
Hilltop Holdings
HTH
$2.11B
| $1.61K | ﹤0.01% |
53
| – | – |
2024 Q4
2 quarters
|
|
|
AVDL
3065
DELISTED
Avadel Pharmaceuticals
AVDL
| $1.6K | ﹤0.01% |
+181
| New | +$1.59K |
2025 Q2
0 quarters
|
|
3066
BioNTech
BNTX
$22.7B
| $1.6K | ﹤0.01% |
15
+12
| +400% | +$1.21K |
2020 Q2
20 quarters
|
|
3067
EverQuote
EVER
$760M
| $1.6K | ﹤0.01% |
66
| – | – |
2024 Q1
5 quarters
|
|
3068
Acadian Asset Management
AAMI
$3.29B
| $1.59K | ﹤0.01% |
45
-25
| -36% | -$727 |
2020 Q1
21 quarters
|
|
3069
NextDecade
NEXT
$1.6B
| $1.58K | ﹤0.01% |
177
-36
| -17% | -$279 |
2022 Q4
10 quarters
|
|
3070
Latham Group
SWIM
$735M
| $1.58K | ﹤0.01% |
247
-98
| -28% | -$570 |
2025 Q1
1 quarter
|
|
3071
ProShares UltraPro Russell2000
URTY
$267M
| $1.57K | ﹤0.01% |
40
| – | – |
2024 Q1
5 quarters
|
|
3072
State Street Multi-Asset Real Return ETF
RLY
$1.43B
| $1.57K | ﹤0.01% |
54
| – | – |
2022 Q1
13 quarters
|
|
3073
JBT Marel
JBTM
$5.5B
| $1.56K | ﹤0.01% |
13
+11
| +550% | +$1.23K |
2024 Q2
4 quarters
|
|
3074
Deluxe
DLX
$1.05B
| $1.56K | ﹤0.01% |
98
+86
| +717% | +$1.29K |
2023 Q2
8 quarters
|
|
3075
Ryanair
RYAAY
$27B
| $1.56K | ﹤0.01% |
27
| – | – |
2022 Q2
12 quarters
|
|
Similar funds
Parallel Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, Parallel Advisors held 3,762 positions worth $5B, up 13% from $4.43B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Parallel Advisors's Q2 2025 filing shows 251 new, 1,450 increased, 1,277 reduced and 224 closed positions. Its largest new stake was Vanguard 0-3 Month Treasury Bill ETF: 32,722 shares worth $2.47M. The largest sale was Corcept Therapeutics, an estimated $7.34M.
By sector, the portfolio is most concentrated in Miscellaneous at 47% of assets, down from 47% a quarter earlier, followed by Technology and Healthcare.
- Parallel Advisors's largest Q2 2025 buy was Vanguard 0-3 Month Treasury Bill ETF: 32,722 shares worth $2.47M.
- Parallel Advisors added most to iShares Core S&P 500 ETF in Q2 2025, an estimated $18.4M increase.
- Parallel Advisors's biggest Q2 2025 reduction was Corcept Therapeutics, cutting an estimated $7.34M.
- Parallel Advisors fully exited Discover Financial Services in Q2 2025, selling an estimated $1.22M.
- Parallel Advisors's ten largest holdings make up 39% of its $5B portfolio in Q2 2025.
- Parallel Advisors opened 251 new positions and closed 224 in Q2 2025.
- Parallel Advisors's portfolio value rose 13% quarter-over-quarter to $5B.
Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.